Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant
form of heart failure worldwide, in tandem with ageing of the general population and the …

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

2022 ESC/ERS pulmonary hypertension guidelines incorporate changes and adaptations
focusing on clinical management https://bit. ly/3QtUvb4

This review aims to provide a translational perspective on recent developments in heart
failure with preserved ejection fraction (HFpEF), linking mechanistic insights to potential …

There is an unmet need for effective treatment strategies to reduce morbidity and mortality in
patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in …

Aims Prevalent right ventricular (RV) dysfunction (RVD) is associated with increased
mortality in patients with heart failure with preserved ejection fraction (HFpEF), but no study …

Approximately half of all patients with heart failure have preserved ejection fraction (HFpEF)
and, as life expectancies continue to increase in western societies, the prevalence of HFpEF …

Aims Pulmonary hypertension (PH) and pulmonary vascular disease (PVD) are common
and associated with adverse outcomes in heart failure with preserved ejection fraction …

Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes
heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic …

Aims The presence of pulmonary hypertension (PH) severely aggravates the clinical course
of heart failure with preserved ejection fraction (HFpEF). To date, neither established heart …